FLU-v

Drug Profile

FLU-v

Alternative Names: FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences) - SEEK; Influenza virus vaccine (FLU-v) – SEEK; Universal influenza vaccine - SEEK

Latest Information Update: 26 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SEEK
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 18 Jun 2018 Efficacy, adverse events and immunogenicity data from a phase IIb trial in Influenza virus infections released by hVIVO
  • 18 Jul 2017 SEEK completes a phase II trial in Influenza virus infections (In volunteers) in Netherlands (SC) (NCT02962908)
  • 25 May 2017 SEEK completes a phase IIb trial in influenza virus infections (In volunteers) in United Kingdom (NCT03180801)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top